Abstract:

Ｏｂｊｅｃｔｉｖｅ：To investigate the new classification of membranoproliferative glomerulonephritis (MPGN).
Ｍｅｔｈｏｄｏｌｏｇｙ：The clinicopathological data of MPGN patients (excluding lupus nephritis) diagnosed by renal biopsy in Nanjing General Hospital from January 2011 to September 2016 were collected and classified according to the new immunofluorescence classification proposed by Mayo Clinic.
Ｒｅｓｕｌｔｓ：Among the 232 patients with MPGN,35（151%）were diagnosed with C3 Glomerulopathy and 197（849%）were diagnosed with immune complexmediated MPGN.The latter composed of 55 patients with monoclonal deposits in the kidney which could be further divided in 44 patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits and 11 patients with renal monoclonal immunoglobulin deposition disease,and 142 patients with polyclonal deposits including 52 infectionrelated cases(HBV/HCV),4 autoimmune related cases,22 cryoglobulinemic related cases,1 case fibrillary glomerulonephritis and 63 cases Idiopathic.The renal survival curve revealed that median survival time was 42 months in monoclonal group,significantly shorter than in  polyclonal group (P=0013).
Ｃｏｎｃｌｕｓｉｏｎ：(1) The new classification of MPGN based on immunofluorescence has practical value in revealing pathogenesis,finding cause and judging prognosis; (2) Monoclonal immunoglobulinopathy and hepatitis virus infection were the first and second etiology of secondary MPGN in our country.

Key words: membraneproliferative glomerulonephritis, new classification, membranoproliferative glomerulonephritis